Banque Pictet Cuts Philip Morris International Stake by 6.9%, Sells $73.2M Position
Banque Pictet & Cie SA reduced its Philip Morris International stake by 6.9% in Q3, selling 33,346 shares to hold 451,341 shares. The position, valued at $73.2 million, accounts for 0.4% of Banque Pictet’s portfolio and ranks as its 24th largest holding.
1. Major Stake Reduction by Banque Pictet & Cie SA
In the third quarter, Banque Pictet & Cie SA reduced its holding in Philip Morris International by 6.9%, selling 33,346 shares and leaving it with 451,341 shares. This position represents approximately 0.4% of the firm’s total investment portfolio, making it the 24th largest holding. Based on the most recent SEC filing, the remaining stake was valued at $73.2 million, indicating a strategic rebalancing within the bank’s asset allocation during the period.
2. Activity Among Smaller Hedge Funds
Several niche asset managers initiated or increased positions in Philip Morris International during the second quarter, though on a modest scale. Legacy Investment Solutions and Traub Capital Management each established new stakes valued at about $25,000. Abound Wealth Management expanded its holding by 566.7% to 160 shares, investing $29,000, while Briaud Financial Planning raised its stake by 266.7% to 165 shares, an outlay of $30,000. Estabrook Capital Management also entered with a $30,000 position. Institutional ownership now stands at 78.6%, underscoring the stock’s strong appeal among large-scale investors.
3. Dividend Policy and Earnings Performance
Philip Morris International declared a quarterly dividend of $1.47 per share, payable January 14 to holders of record on December 26, translating to an annualized yield of 3.7% and a payout ratio exceeding 100%. In the latest quarter, the company reported revenue of $8.12 billion and earnings per share of $1.59. Analysts project full-year EPS of 7.14, reflecting confidence in robust cash flow generation despite a current return on equity of negative 122.1%—a function of significant share repurchases and balance sheet leverage.
4. Analyst Ratings and Price Targets
Research houses maintain a generally bullish stance, with 12 Buy ratings and one Hold rating on the stock. Morgan Stanley and Barclays assign overweight ratings, setting price objectives at $175 and $180 respectively, while JPMorgan Chase and Co. recently trimmed its target to $185. The consensus target price stands at $189, suggesting upside potential of roughly 15% from recent trading levels. The average valuation multiples are 22 times forward earnings and a PEG ratio of 1.92, reflecting high growth expectations for the company’s smoke-free product portfolio.